HC Wainwright & Co. Maintains 'Buy' Rating for Myomo (MYO), Lowers Price Target to $5.00

Analyst Sean Lee from HC Wainwright & Co. has maintained a "Buy" rating for Myomo (MYO) but lowered the price target to $5.00 from $9.50. This represents a 47.37% decrease. Myomo is a wearable medical robotics company that develops myoelectric orthotics for people with neuromuscular disorders. The average one-year price target for MYO is $8.70, with an average target implying an upside of 394.32%. The estimated GF Value for MYO in one year is $3.01, suggesting a 71.02% upside from the current price.

Analyst Sean Lee from HC Wainwright & Co. has maintained a "Buy" rating for Myomo (MYO) but lowered the price target to $5.00 from $9.50. This represents a 47.37% decrease. Myomo is a wearable medical robotics company that develops myoelectric orthotics for people with neuromuscular disorders.

The adjustment reflects a significant change in the analyst's outlook on Myomo's stock performance. The new price target of $5.00 suggests a more conservative estimate compared to the previous target of $9.50.

The average one-year price target for MYO, as per the consensus of five analysts, stands at $8.70. This average target implies an upside of 394.32% from the current price of $1.76. Additionally, the estimated GF Value for MYO in one year is $3.01, suggesting a 71.02% upside from the current price.

The latest earnings call provided insights into Myomo's second-quarter performance. The company reported a 28% increase in revenue to $9.7 million, driven by a higher number of revenue units and a higher average selling price (ASP). However, the company also reported an operating loss of $4.6 million, up from $1.1 million in the prior year quarter.

Management acknowledged recent operational challenges, including lower lead quality and increased cost per pipeline add. They also highlighted efforts to improve lead conversion rates and reduce operating expenses. The company's focus on the orthotics and prosthetics (O&P) channel and international expansion, particularly in Germany, was noted as areas of growth.

Analysts and investors should closely monitor Myomo's ability to navigate these challenges and execute its growth strategy. The company's performance in the third quarter and beyond will be critical in determining its stock's potential upside.

References:

[1] https://www.gurufocus.com/news/3055526/analyst-lowers-price-target-for-myomo-myo-to-500-myo-stock-news
[2] https://seekingalpha.com/news/4483588-myomo-outlines-revised-2025-revenue-growth-target-of-23-percentminus-29-percent-as-lead